Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Arnott

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
The American Journal of Gastroenterology|March 6, 2009
Fecal calprotectin predicts the clinical course of acute severe ulcerative colitisG T Ho, H M Lee, G Brydon, et al.
Alimentary Pharmacology & Therapeutics|December 18, 2007
The use of adalimumab in the management of refractory Crohn's diseaseG-T Ho, L Smith, S Aitken, et al.
Frontline Gastroenterology|December 30, 2021
Inflammatory bowel disease clinical service recovery during the COVID-19 pandemicShahida Din, Daniel Gaya, Jochen Kammermeier, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2022
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's diseaseLauranne A A P Derikx, Nikolas Plevris, Shanna Su, et al.
Gut|June 5, 2008
Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitisC L Noble, A R Abbas, J Cornelius, et al.
Digestive Diseases and Sciences|December 12, 2018
Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World OutcomesNikolas Plevris, Gareth R Jones, Philip W Jenkinson, et al.
Inflammatory Bowel Diseases|October 19, 2018
Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic RemissionNikolas Plevris, Mathew Lyons, Philip W Jenkinson, et al.
Frontline Gastroenterology|August 15, 2023
Establishing key performance indicators for inflammatory bowel disease in the UKMohammed Nabil Quraishi, Elizabeth Dobson, Rachel Ainley, et al.
Gastroenterology|August 30, 2008
Definition of phenotypic characteristics of childhood-onset inflammatory bowel diseaseJohan Van Limbergen, Richard K Russell, Hazel E Drummond, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Gastroenterology|August 1, 2024
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitisBeatriz Gros, Hannah Ross, Maureen Nwabueze, et al.
The American Journal of Gastroenterology|March 6, 2009
Fecal calprotectin predicts the clinical course of acute severe ulcerative colitisG T Ho, H M Lee, G Brydon, et al.
Alimentary Pharmacology & Therapeutics|December 18, 2007
The use of adalimumab in the management of refractory Crohn's diseaseG-T Ho, L Smith, S Aitken, et al.
Frontline Gastroenterology|December 30, 2021
Inflammatory bowel disease clinical service recovery during the COVID-19 pandemicShahida Din, Daniel Gaya, Jochen Kammermeier, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 25, 2022
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's diseaseLauranne A A P Derikx, Nikolas Plevris, Shanna Su, et al.
Gut|June 5, 2008
Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitisC L Noble, A R Abbas, J Cornelius, et al.
Digestive Diseases and Sciences|December 12, 2018
Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World OutcomesNikolas Plevris, Gareth R Jones, Philip W Jenkinson, et al.
Inflammatory Bowel Diseases|October 19, 2018
Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic RemissionNikolas Plevris, Mathew Lyons, Philip W Jenkinson, et al.
Frontline Gastroenterology|August 15, 2023
Establishing key performance indicators for inflammatory bowel disease in the UKMohammed Nabil Quraishi, Elizabeth Dobson, Rachel Ainley, et al.
Gastroenterology|August 30, 2008
Definition of phenotypic characteristics of childhood-onset inflammatory bowel diseaseJohan Van Limbergen, Richard K Russell, Hazel E Drummond, et al.
Pageof 8